drugset
drugset / Trial / NCT02324699

Corticosteroids With Vedolizumab in Crohn's Disease

NCT02324699 ↗

Phase 4 Terminated 1 enrolled Icahn School of Medicine at Mount Sinai Takeda · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Use of co-induction with corticosteroid therapies may accelerate the remission rate when used with vedolizumab. Further, this may lead to higher rates of response and remission at week 10 than would be seen with vedolizumab monotherapy.

Timeline

Start
2016-04
Primary completion
2018-02-08
Completion
2018-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified 40 mg —
Background Vedolizumab Monoclonal antibody 300 mg Intravenous

Indications

Crohn disease